Federated Hermes
CBIO

Federated Hermes’s Crescent Biopharma CBIO Stock Holding History

Federated Hermes’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-34
Closed -$4.28K – 2156
2023
Q1 		$4.28K Sell
34
-6
-15% -$1.35K ﹤0.01% 1950
2022
Q4 		$12.2K Sell
40
-11
-22% -$1.62K ﹤0.01% 1847
2022
Q3 		$3K Hold
51
– – ﹤0.01% 1934
2022
Q2 		$3K Sell
51
-2,120
-98% -$157K ﹤0.01% 1945
2022
Q1 		$248K Sell
2,171
-1,284
-37% -$151K ﹤0.01% 1565
2021
Q4 		$497K Buy
3,455
+9
+0.3% +$1.63K ﹤0.01% 1482
2021
Q3 		$755K Buy
3,446
+10
+0.3% +$2.12K ﹤0.01% 1380
2021
Q2 		$797K Buy
3,436
+10
+0.3% +$2.54K ﹤0.01% 1381
2021
Q1 		$1.03M Sell
3,426
-704
-17% -$252K ﹤0.01% 1361
2020
Q4 		$1.55M Sell
4,130
-869
-17% -$305K ﹤0.01% 1163
2020
Q3 		$1.53M Sell
4,999
-10
-0.2% -$3.82K ﹤0.01% 1081
2020
Q2 		$1.88M Buy
5,009
+563
+13% +$159K ﹤0.01% 1014
2020
Q1 		$1.01M Buy
4,446
+3,068
+223% +$1.17M ﹤0.01% 1135
2019
Q4 		$729K Buy
+1,378
New +$746K ﹤0.01% 1359
2018
Q1 		– Sell
-9
Closed -$16K – 2178
2017
Q4 		$16K Buy
+9
New +$11.9K ﹤0.01% 1805
2015
Q3 		– Sell
-1
Closed -$1K – 2001
2015
Q2 		$1K Buy
+1
New +$827 ﹤0.01% 1899

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes's CBIO Position: Q2 2023 in Review

Federated Hermes sold out of Crescent Biopharma (CBIO) in Q2 2023, closing a stake of 34 shares — an estimated $4.28K sold.

Federated Hermes first reported a position in CBIO in Q2 2015 and held it in 16 quarters. The position peaked at $1.88M in Q2 2020. 55 funds tracked by Wall St. Rank hold CBIO as of Q2 2023.

  • Federated Hermes reported no remaining Crescent Biopharma position as of Q2 2023 after selling out during the quarter.
  • Federated Hermes sold 34 Crescent Biopharma shares in Q2 2023, an estimated $4.28K.
  • Federated Hermes first reported a position in Crescent Biopharma in Q2 2015 and held it in 16 quarters.
  • Federated Hermes's Crescent Biopharma position peaked at $1.88M in Q2 2020.
  • 55 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2023.

Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.